Glaxo trade secret claim in Zantac case rejected by Judge Boyle.
This article was originally published in The Tan Sheet
Executive Summary
GLAXO TRADE SECRET CLAIMS REJECTED IN ZANTAC CASE AGAINST NOVOPHARM by Raleigh, N.C. federal court Judge Terrence Boyle in his July 5 ruling in the ranitidine patent case. Glaxo Wellcome's trade secret misappropriation claims against Novopharm "do not withstand even cursory examination under law," Boyle stated.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning